l Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards India’s only dedicated celebration of excellence in healthcare innovation, pharmaceutical & medical excellence and brand transformation.Pharmaleaders attempt is to recognize and celebrate science and innovation in the pharmaceutical, biotechnology, lifescience & healthcare industry. At the celebration day of the Awards, Companies, Academics, Partners, Government and Delegates get a glimpse of Pharmaleaders’s ongoing research and a walk through of the Network 7 Media Group ’s most recent innovations in the complex field of understanding & analyzing genes of the healthcare industry as Pharmaleaders feel that “no one understands the returning the smiles to the achievers they deserve most” “Regarding the 2014, the 7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014, we have been honoring outstanding scientific contributions for more than a decade and are privileged to recognize the work of accomplished leaders “As a true friend, philosopher & guide, we are deeply committed to creating a more sustainable future through scientific research and we will continue to support visionary pharma leaders as they strive to advance our understanding in all fields of the pharmaceutical & healthcare industry. “The Pharmaceutical Leadership & Pharmaleaders Business Leadership Awards” was first bestowed in India in 19991 In order to reflect the increasingly global nature of the awards, it was then revaluated & reshaped in more credible formats in the year 2008 & since than these awards serve as a benchmark of innovation.

1. Developed by
6th
Annual
Pharmaceutical
Leadership Summit
2013TM
Pharmaceutical Leadership Summit &
Business Leadership Awards 2013
6th
Annual
Pharmaceutical
Leadership Summit
2013TM
6th Annual
GET READY TO ATTEND ASIA’S
BIGGEST LEADERSHIP
EXPERIENCE IN HEALTH CARE
6th ANNUAL PHARMACEUTICAL LEADERSHIP
SUMMIT & BUSINESS LEADERSHIP AWARDS 2013
INCREDIBLE PHARMALEADERS 2013
BILLION DREAMS-PUSHING INDIA'S GROWTH AGENDA
Friday,27st December 2013 ,Hotel Hilton,
Mumbai Intercontinental, Airport,Mumbai,India
INCRED BLE
BILLION DREAMS
PUSHING INDIA’’’SGROWTHAGENDA
Friday, 27th December, 2013, Hotel Hilton, Mumbai International Airport, India
Pharma
Leaders
2013
POWER
BRAND
brating
llence in
thcare
vations
1999
Cele
Exce
Heal
Inno
Since

2. The
game
changer
Satya Brahma
Chairman & Editor -in-Chief-Pharmaleaders
Dear
Colleague...
6th
Annual
Pharmaceutical
Leadership Summit
2013TM
India's pharma market has evolved and shifted gears to set foot on an accelerated growth path. In conclusion, as emerging
markets become increasingly important and India's role among these becomes progressively significant, both domestic and
pharma MNCs will need to adapt their business models, organisations and processes and create customised strategies.
Overall, active participation from domestic and international pharma companies, increased investments and strategic initiatives
will likely underpin future growth and enable the Indian pharma market to break into the global top tier in the present decade.
ICRAexpects 10-12% growth for pharma industry in 2013-14 ICRAhas come out with industry update release on pharma sector.
The research firm, expects the industry to revert to a growth of 10-12% in 2013-14. The impact of new DPCO though expected to
be limited, could also get offset by volume expansion and efforts of industry participants to take price hike in rest of the
portfolio.Growth opportunities intact but managing industry challenges remains key for Indian Pharmaceutical Industry: ICRA
Despite the high-base of the previous year, ICRA believes that the Indian Pharmaceutical industry would continue to experience
strong growth in the near- term however there would some moderation in the growth trajectory. Principally, the generic
opportunities in US will continue to drive revenue growth for Indian pharma companies. This would be an outcome of a) the
sizeable generic opportunity (drugs with brand value of USD 80 billion are expected to face generic competition) over the next 4-5
years, b) strong product pipeline of pending ANDAs with high increasing proportion of complex generics and c) market share
improvement given the relatively small base (share of leading Indian companies is less than 10 percent in the U.S. generics
space). In addition, acquisitions by Indian companies to add technical capabilities and focus on strengthening branded business
(albeit on a small scale) are also likely to drive growth going forward as companies feel the need to diversify.
While growth momentum in the domestic formulation industry slowed down in 2012-13 owing to a confluence of reasons
(discussed above), ICRAbelieves that the industry would revert to its long-term growth trajectory in the medium-term as structural
growth drivers continue to remain impervious. The growth momentum has picked-up over the past few months and with pricing
policy related matters behind us, ICRA expects the industry to revert to a growth of 10- 12 percent in 2013-14. The impact of new
DPCO though expected to be limited, could also get offset by volume expansion and efforts of industry participants to take price
hike in rest of the portfolio. In Europe, the performance of Indian companies improved in 2012-13 in comparison to the prior year
led by primarily new product launches which helped to offset the impact of pricing pressure.
However, given the pace of healthcare reforms and the way competitive landscape is changing in Europe, ICRAbelieves that the
performance of generic companies would remain contingent on new product introductions. As many of the European markets are
gradually shifting character from being 'branded generic' to 'un-branded generic' and from being 'physician-influenced' to 'payor-influenced,
a relook at business plans also appears to be a common theme across companies. Generics companies are
increasingly focusing on expanding presence in relatively underpenetrated markets (i.e. France, Spain & Italy), branded generic
markets of East Europe and niche areas like complex generics, OTCs etc. In general, Indian pharma companies generate a
relatively lower share of revenues from Europe with profitability also subdued compared to other markets. In addition US
generics, emerging markets present one of the most promising growth opportunities for Indian pharmaceutical companies. As
growth prospects normalize in developed markets, companies are increasingly focusing on emerging markets through portfolio
expansion, alliances or JVs and acquisitions, says ICRA. According to ICRA, given the distinct nature of some of the markets
being tapped, managing regulatory hurdles (i.e. delays in receiving approvals in Brazil, healthcare reforms in Russia) and
execution however remains the key. Indian companies though have an inherent advantage given their experience with 'branded
generics' in India. Amongst new frontiers, evolving generic market in Japan (world's second largest pharmaceutical market with
only 23 percent generic penetration) and biosimilars provide alternative growth prospects for Indian companies.
I take this opportunity to invite you to be the part of this historic 6th Edition of Pharmaceutical Leadership Summit & Business
Leadership Awards 2013. I hope your presence at the summit will be an enlightened one.

3. THEME
INCRED BLE
Incredible Pharmaleaders 2013. – " Pushing India's
Growth Agenda-" is the theme of the historic edition
of Pharmaleaders's 6th Leadership Summi t &
Pharmaleaders Business Leadership Awards 2013 to
be staged in Mumbai on 27th Year, the much anticipated &
awaited prestigious title is current state of affairs & the BILLION DREAMS
attempting to revisit the
pressure of building brands
& mo s t imp o r t a n t l y, maintaining the sustainable
growth record in an era PUSHING INDIA’’’SGROWTHAGENDA
where Government's policy
making machine making a Friday, 27th December, 2013, Hotel Hilton, Mumbai International Airport, India
difficult task to the thinking
process & the strategies to retain market dominance. As
Pharmaleader s mar ch ahead to host the event, both
domestic & international markets have been witnessing a change of approach. The Price war, US FDA
Vigilance, FDI & Generics are the key
drivers that will determine the winning combinations.December 2013 in the commercial capital of India,
Mumbai. Entering in its 6thIndian markets are far more mature and have given their thumbs down to the
controversial Food Security Bill. But the UPA government will do all it takes to indulge in such populist
measures even going to the extent of driving the country down the fiscal drain. Fiscal deprivation just adds
on to the long list of pitfalls of the UPA government including corruption, apathy, indecision and pseudo
secularism. Its time for the people of India to fight back. Otherwise its the middle class and the hapless poor
who will pay the price for supporting such a corrupt and inept regime. Pharmaleaders feel the heat when
finding the right perspectives as the overwhelming numbers suggest that the Pricing Policy of the
Government have taken a toll signaling the death of investments in R & D in the absence of a strong
patent regime.
However, the new Drug Prices Control Order (DPCO) 2013 seems to be forcing doctors and patients to
turn to substitutes, courtesy a silent protest by chemists across the state. Chemists are unhappy because
with the DPCO retail chemists are losing 7% commission while wholesalers, about 3% on each drug sold.
Chemists claimed that only 40% of pharma companies in the state have so far agreed to match their
margins. In a landmark decision, the DPCO has lowered prices of 348 essential drugs to bring them within
the reach of every patient.However, it seems a tough time is looming for patients; examine the many
challenges facing the industry and the policy options open to the Indian government to avert an impending
crisis in its capacity to continue the production of cheap generics.
The government of India implemented a series of policy measures in the 1970s to achieve self-sufficiency in
pharmaceutical production. The first step was to revamp the colonial patent legislation and abandon product
patent protection for medicines. Hence, the Patents Act 1970 allowed only process patent protection for
pharmaceutical inventions. As a result, Indian companies could produce new medicines which had been
introduced in the international market but were not available to needy patients in India. This made possible
the production and sale of new medicines at affordable prices.Secondly, the government introduced control
measures on foreign ownership under which foreign companies were not allowed to hold more than 50% of
equity.Thirdly, the government introduced direct price control on all formulations of about 347 bulk
drugs.Fourthly, pharmaceutical multinational corporations (MNCs) were forced to start production of both
formulation and bulk drugs in India.Fifthly, public sector production of bulk drugs encouraged the small and
medium enterprise (SME) sector to start formulation.Within a span of some 20 years, these policy initiatives
cumulatively made India not only self- sufficient but also a net exporter of generic medicines.
www.pharmaleaders2013.com

4. Glimpses of the Magic Moments
POWER Annual
www.pharmaleaders2013.com
INCRED BLE
BILLION DREAMS
PUSHING INDIA’’’S GROWTHAGENDA
Friday, 27th December, 2013, Hotel Hilton, Mumbai International Airport, India
6th
Pharmaceutical
Leadership Summit
2013TM
Pharma
Leaders
2013
BRAND
www.pharmaleaders2013.com

5. Glimpses of the Magic Moments
Pharma
Leaders
2013
POWER
BRAND
www.pharmaleaders2013.com
INCRED BLE
BILLION DREAMS
PUSHING INDIA’’’S GROWTHAGENDA
Friday, 27th December, 2013, Hotel Hilton, Mumbai International Airport, India
www.pharmaleaders2013.com

6. AGENDA 6th
Friday, December 27, 2013
2:00PM - 3:00PM Registration, Reception & Networking High Tea
PROGRAM AGENDA :
6th Annual Pharmaceutical Leadership
Annual
Summit & Pharmaleaders Business Leadership Awards 2013
Opening Address & Summit Moderation
Market Leader ( Life Sciences).Future Steps
( A Korn/Ferry Company)
3:00PM - 3:10PM Mr. S. Krishnakumar (KK),
Theme & Welcome Address
Mr. Satya Brahma
Chairman & Editor-In-Chief –
Pharmaleaders Group
Inaugural Address :
The Rise of India as a Healthcare
powerhouse in the world
Mr. Daara Patel
Secretary General, IDMA
(Indian Drug Manufacturers Association)
Keynote Address
Decoding the success mantra of Indian Pharma
Industry in an era of Govt regulations.
Promoter Director,Salus Lifecare Pvt Ltd
Mr. Kewal Kanda,
Keynote Address
Dr Mukesh Batra,
Founder Chairman, Dr Batra's Positive Health Clinic
Challenges of Globalizing Homeopathic Medicines :
A Dr Batra's Case Study
www.pharmaleaders2013.com
3:10PM - 3:20PM
3:20PM - 3:40PM
3:40PM - 4:00PM
4:00PM - 4:25PM
Pharmaceutical
Leadership Summit
2013TM

7. Government's Perspective
Regulatory Challenges of Indian Plants.
FDA Initiative to curb counterfeit drugs.
Commissioner FDA,
Mr.Mahesh Zagade,
Maharashtra, Government of Maharashtra
The Evolving Profile of the Indian Medical Practioners:
Doctors Expectations from the Pharmaceutical Companies
– Beyond Gifts & Vacation Sponsorships
Dr Shasank. R. Joshi
Consulting Endocrinologist
Panel Discussion: Ethics in Medical Pofession
Dr. Chytra V Anand
Founder&CEO &
Chief Cosmetic Dermatologist
KOSMODERMA
Chairperson
Dr. Siddharth N. Shah
Consulting Physician & Diabetologist
Esteemed Panel Members
Dr.Jothydev Kesavadev
Founder Chairman,
Jothydev's Diabetes
Research Centre
Dr. Rashmi Shetty
Non-Surgical Aesthetic
Medicine Expert
Dr. Kaushal Pandey
Cardiac Surgeon
Dr Shashank R Joshi
Physician Endocrinologist &
Dialectologist
Dr. Sudhir Vaishnav
Interventional Cardiologist
Dr Deepak K Jhumani
Consultant in Sexual
Health and Counsellor
Dr. Harish S. Bhende
Orthopaedic Surgeon,
Dr Laud Clinic.
www.pharmaleaders2013.com
4:25PM - 4:40PM
4:40PM - 5:00PM
5:00PM - 5:30PM
Dr. Deepak Chaturvedi
Physician Endocrinologist & Dialectologist

8. Keynote Address
Dr. Hasit Joshipura
Managing Director, GlaxoSmithKline
Pharmaceuticals Ltd
5:30PM - 5:45PM
Has the Pharmaceutical Companies failed to
impress the doctors on medical education by
adopting unethical means?
Mr. Deepak Naik,
Managing Director, Health 'N' U Therapeutics Pvt. Ltd
5:45PM - 6:00PM
6:00PM - 6:25PM Refreshment Break & Networking
FDI in Pharma. FDI policy of the
Govt to protect domestic generic (off-patent) firms.
Dr.GSK Velu
Founder Chairman, Trivitron Group of Companies
6:35PM - 7:00PM Panel Discussion : The Changing Face of Pharmaleaders
Making of India's Leadership in Medical
Innovation : The Real Time Experience
Dr Naresh Trehan
Cardiovascular and Cardiothoracic Surgeon & CMDS,Medanta
6:25PM - 6:35PM
7:00PM - 7:30PM
The Changing Face of Indian Skin care Innovations
Dr. Shuba Dharmana
Cosmetic Dermatologist CEO & Founder,
Le'jeune Medspa
7:30PM - 7:45PM
Cost effective Healthcare through citizens
community participation
Prof. Dr. Nandkishore
Shamrao Laud
Founder, Dr Laud Clinic
7:45PM - 8:00PM
08.00 pm onwards 6th Annual Pharmaceutical Leadership Summit &
Business Leadership Award 2013 followed by Cocktail & Gala Dinner.

9. 6th
Annual
Pharmaceutical
Leadership Summit
2013TM
REGISTER TODAY
Ticket to this event include all panels, forums, networking,
high tea, dinner, cocktail, award presentation ceremony &
of course cultural extravaganza.
For Group Bookings or
Enquiry, Please contact
Our Event Team At : registrations@pharmaleaders2013.com
INCREDIBLE PHARMALEADERS 2013
BILLION DREAMS – PUSHING INDIA'S GROWTH AGENDA
Friday, 27st December 2013, Hotel Hilton, Mumbai Intercontinental, Airport, Mumbai, India
6th ANNUAL PHARMACEUTICAL LEADERSHIP
SUMMIT & BUSINESS LEADERSHIP AWARDS 2013
REGISTRATION APPLICATION
Registration Informations:
Per Delegate Fees: INR RS 10000 + 12.36 SERVICE TAX
We are pleased to nominate the following participant(s) for the Summit:
Sr : Name : Designation: Email id :
1.______________________________ _______________________ _______________
2.______________________________ _______________________ _______________
3.______________________________ _______________________ _______________
The DD / Cheque No. ________________ for Rs. ________________ towards the delegate fee drawn in favour of
“Dreamz Activations”, payable at Mumbai is enclosed.
Name:________________________________________________Designation :____________
Company:_____________________________________
Address:_______________________________________________________________________________
Telephone:__________________________Fax:_________________________Mobile:_________________
Email:_________________________________________Website:_________________________________
ØPre-Registration and Pre-Payment is a must
Summit Secretariat & Registration Desk.
Dreamz Activations Unit No. 53, 2nd Floor, Aditya Industrial, Estate, CTS No. 1068 - C, Plot No.444 ( P ), Devrukhkar
Wadi, Chincholi Bunder Road, Malad ( W ), Mumbai - 400 064. Phone: + 91 22 4248 1234 / 4248 1235. Email :
pharmasummit2013@webevents.co.in / anish@dreamzactivations.com
Terms & Conditions
ØA 10% discount for 3 or more delegates
Delegate fee non-refundable but change in nomination accepted
Ø
www.pharmaleaders2013.com

10. Individual Non-Voting Award Categories
Business Leader of the Decade India's Most Admired Homeopathic Brand 2013
Incredible Medical Expert of the Decade. (Individual Awards by Jury)
www.pharmaleaders2013.com
Dr Naresh Trehan
Founder Chairman,
Medanta
Prof. Dr. Nandkishore Shamrao Laud
Founder, Dr Laud Clinic
Global Indian of the Year 2013
Mr. Satish Ramanlal Mehta
CEO & MD,
Emcure Pharmaceuticals Limited
Padma Shri Dr. Viswanathan Mohan
Founder & CEO
Dr. Mohan's Diabetes Specialties Centre.
Dr Shasank R Joshi
Consulting Endocrinologist &
Founder, Joshi Clinic
Dr.Jothydev Kesavadev
Founder Chairman,
Jothydev's Diabetes Research Centre
Dr. Kaushal Pandey
Cardiac Surgeon, Jaslok Hospital
Dr. K. Ravindranath
CMD, Global Hospitals Group HelthCare Visionary of the Decade

11. Individual Non-Voting Award Categories
Mr. D.C. Jain
Chairman, Akums Drugs &
Pharmaceuticals Ltd.
www.pharmaleaders2013.com
Lifetime Achievement Award 2013
Pioneering Innovation in Stem Cell Banking Award 2013
Emerging Hospital Chain of the Year 2013
Entrepreneur of the year 2013
Dr G.S.K. Velu
CEO & Managing Director
Trivitron Healthcare
Rising Brand of the Year 2013 Transformational Leader of the Decade
Business Leader of the year
(Healthcare & IT) 2013
Non-Surgical Aesthetic Medicine Expert 2013
Dr. Rashmi Shetty,
CEO & Founder,Ra Skin & Aesthetcs
Mr. Upinder Zutshi
CEO & MD, Infinite Computers (I) Ltd.
Dr Mukesh Batra
Founder Chairman,
Dr Batra's Positive Health Clinic

12. INCRED BLE
BILLION DREAMS
PUSHING INDIA’’’SGROWTHAGENDA
Friday, 27th December, 2013, Hotel Hilton, Mumbai International Airport, India
6th
Annual
Pharmaceutical
Leadership Summit
2013TM
Pharma
Leaders
2013
POWER
BRAND
The Emerging Leader
in SKINCARE innovation